Biosyntech

About:

Biosyntech is engaged in the development of biotherapeutic thermogels for tissue repair and the delivery of therapeutic agents.

Website: http://www.biosyntech.com

Top Investors: Fonds de solidarité FTQ, BDC Venture Capital, Highland Capital Partners, Pappas Ventures, ProQuest Investments

Description:

BioSyntech, Inc. develops biotherapeutic thermogels designed for tissue repair and delivery of therapeutic agents. Its technology platform is BST-Gel, a family of hydrogels based on chitosan, a natural biopolymer derived from crustacean shells. The company’s lead products in clinical trials include BSTCarGel for cartilage repair; BST-DermOn for wound healing; and BST-InPod for the treatment of chronic pain due to plantar fat pad atrophy in the heel and forefoot. Biosyntech has a collaboration with Nicholas Piramal India, Ltd. to involve in the clinical studies for BST-InPod, which is being developed to alleviate the chronic pain associated with foot fat pads. The company was incorporated in 1994 and is headquartered in Laval, Canada.